Author: Christaphine Bob-Ray

On October 8, 2021, the FDA approved Rethymic, marking a life-changing day of hope for children with congenital athymia and their families. Rethymic is not only the first, it is also the only treatment option that rebuilds the immune system for pediatric congenital athymia approved by the FDA. The scientists at Enzyvant have been researching this treatment option for 25 years. Their dedication was inspired by the world of possibilities in store for children with this rare disease, if only they could live past their 3rd birthday. Pediatric congenital athymia is a rare disease found in 17-24 live births in…

Read More